- Home
- REI vs AARD Comparison
REI vs AARD Comparison
Compare REI & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REI
- AARD
- Stock Information
- Founded
- REI 2004
- AARD 2017
- Country
- REI United States
- AARD United States
- Employees
- REI N/A
- AARD N/A
- Industry
- REI Oil & Gas Production
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- REI Energy
- AARD Health Care
- Exchange
- REI Nasdaq
- AARD Nasdaq
- Market Cap
- REI 208.6M
- AARD 186.3M
- IPO Year
- REI N/A
- AARD 2025
- Fundamental
- Price
- REI $1.09
- AARD $16.08
- Analyst Decision
- REI
- AARD Strong Buy
- Analyst Count
- REI 0
- AARD 7
- Target Price
- REI N/A
- AARD $31.43
- AVG Volume (30 Days)
- REI 2.5M
- AARD 238.4K
- Earning Date
- REI 11-05-2025
- AARD 11-14-2025
- Dividend Yield
- REI N/A
- AARD N/A
- EPS Growth
- REI N/A
- AARD N/A
- EPS
- REI 0.35
- AARD N/A
- Revenue
- REI $318,900,835.00
- AARD N/A
- Revenue This Year
- REI N/A
- AARD N/A
- Revenue Next Year
- REI $9.58
- AARD N/A
- P/E Ratio
- REI $3.16
- AARD N/A
- Revenue Growth
- REI N/A
- AARD N/A
- 52 Week Low
- REI $0.72
- AARD $4.88
- 52 Week High
- REI $1.81
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- REI 56.57
- AARD 79.19
- Support Level
- REI $1.04
- AARD $10.75
- Resistance Level
- REI $1.18
- AARD $14.32
- Average True Range (ATR)
- REI 0.06
- AARD 1.07
- MACD
- REI -0.00
- AARD 0.58
- Stochastic Oscillator
- REI 52.50
- AARD 95.99
About REI Ring Energy Inc.
Ring Energy Inc is an independent exploration and production company based in The Woodlands, Texas and is engaged in oil and natural gas development, production, acquisition, and exploration activities currently focused in the Permian Basin of Texas. The drilling operations of the company target the oil and liquid rich producing formations in the Northwest Shelf, the Central Basin Platform and the Delaware Basin all of which are part of the Permian Basin in Texas.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.